Financial PerformancePODD reported Q3 revenue of $543.9M, ahead of both internal and consensus estimates, indicating strong performance.
Market ExpansionInsulet has a first mover advantage with on-label automated insulin delivery for Type 2 diabetes.
Product IntegrationOmnipod 5 being compatible with Abbott’s leading CGM, FreeStyle Libre 2 Plus, is an incremental positive for Insulet.